47 related articles for article (PubMed ID: 38529413)
1. Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview.
Seane EN; Nair S; Vandevoorde C; Joubert A
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794172
[TBL] [Abstract][Full Text] [Related]
2. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives.
Pu J; Liu T; Wang X; Sharma A; Schmidt-Wolf IGH; Jiang L; Hou J
Exp Hematol Oncol; 2024 Apr; 13(1):45. PubMed ID: 38654286
[TBL] [Abstract][Full Text] [Related]
3. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
4. Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway.
Pu J; Sharma A; Liu T; Hou J; Schmidt-Wolf IG
Clin Transl Immunology; 2024; 13(3):e1500. PubMed ID: 38529413
[TBL] [Abstract][Full Text] [Related]
5. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
[TBL] [Abstract][Full Text] [Related]
6. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
Front Immunol; 2021; 12():731767. PubMed ID: 34691037
[TBL] [Abstract][Full Text] [Related]
7. Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma.
Nwangwu CA; Weiher H; Schmidt-Wolf IGH
Hematol Oncol; 2017 Dec; 35(4):719-725. PubMed ID: 27430430
[TBL] [Abstract][Full Text] [Related]
8. Increase of Antitumoral Effects of Cytokine-Induced Killer Cells by Antibody-Mediated Inhibition of MICA Shedding.
Wu X; Zhang Y; Li Y; Schmidt-Wolf IGH
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645836
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
Wu X; Tao Y; Hou J; Meng X; Shi J
Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050
[TBL] [Abstract][Full Text] [Related]
10. Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment.
Pu J; Liu T; Sharma A; Schmidt-Wolf IGH
BMC Med Genomics; 2023 Nov; 16(1):295. PubMed ID: 37978516
[TBL] [Abstract][Full Text] [Related]
11. Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells.
Wang Y; Sharma A; Ge F; Chen P; Yang Y; Liu H; Liu H; Zhao C; Mittal L; Asthana S; Schmidt-Wolf IGH
Front Oncol; 2023; 13():1157366. PubMed ID: 37274234
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase-based dual targeted inhibition in multiple myeloma.
Ferro A; Pantazaka E; Athanassopoulos CM; Cuendet M
Med Res Rev; 2023 Nov; 43(6):2177-2236. PubMed ID: 37191917
[TBL] [Abstract][Full Text] [Related]
13. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective.
Sharma A; Schmidt-Wolf IGH
J Exp Clin Cancer Res; 2021 Dec; 40(1):388. PubMed ID: 34886895
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.
Zhou YB; Zhang YM; Huang HH; Shen LJ; Han XF; Hu XB; Yu SD; Gao AH; Sheng L; Su MB; Wei XL; Zhang Y; Zhang YF; Gao ZW; Chen XY; Nan FJ; Li J; Hou J
Acta Pharmacol Sin; 2022 Apr; 43(4):1091-1099. PubMed ID: 34341512
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
